School of Life Sciences, B.S. Abdur Rahman Crescent Institute of Science and Technology, Chennai, India.
School of Life Sciences, B.S.Abdur Rahman Crescent Institute of Science and Technology, Chennai, India,
Front Biosci (Landmark Ed). 2020 Mar 1;25(9):1636-1654. doi: 10.2741/4871.
This review is a concise summary of studies involving the design, synthesis and characterization of potential inhibitors against thymidylate kinase of . Tuberculosis inspite of being an ancient still continues to be a leading cause of death in the world. The increasing emergence of drug resistant is one of the challenges in the complete elimination of tuberculosis. Thus, there is an undeniable need to develop novel treatment strategies to combat this deadly pathogen. Several protein targets are being investigated in with an aim to develop the most potent and selective antituberculosis agents. It is not surprising that protein kinases, the key regulators of metabolism in almost all organisms are one of the major targets explored in antituberculosis drug discovery. Thymidylate kinases, a well established antiviral and anticancer target has garnered significant attention in the past twenty years in the development of prospective antituberculosis agents. A comprehensive analysis of such studies will provide a better understanding on the druggability of thymidylate kinase and also, will enable to refine the future drug designing studies on this attractive drug target of .
这篇综述是对涉及设计、合成和表征结核分枝杆菌胸苷酸激酶潜在抑制剂的研究的简要总结。尽管结核病是一种古老的疾病,但它仍然是世界上主要的死亡原因之一。耐药结核分枝杆菌的不断出现是彻底消除结核病的挑战之一。因此,开发新的治疗策略来对抗这种致命病原体是不可否认的需要。目前正在对结核分枝杆菌进行几种蛋白质靶标的研究,目的是开发最有效和选择性的抗结核药物。丝氨酸/苏氨酸蛋白激酶,几乎所有生物体代谢的关键调节剂,是抗结核药物发现中探索的主要靶标之一,这并不奇怪。胸苷酸激酶是一种成熟的抗病毒和抗癌靶点,在过去二十年中,在开发有前途的抗结核药物方面引起了广泛关注。对这些研究进行全面分析将更好地了解胸苷酸激酶的可药性,并使针对结核分枝杆菌这一有吸引力的药物靶标的未来药物设计研究得到改进。